source
- BioNTech's anti-CTLA-4 drug shows survival advantage in advanced squamous lung cancer at WCLCBioNTech, together with partner OncoC4, presented new overall survival data at the World Conference on Lung Cancer in South Korea, joining other companies such as Summit Therapeutics, GSK and Roche…
- Corbus reports phase 1b obesity data showing lower neuropsychiatric side effects for CB1 antagonistCorbus Pharmaceuticals released results from a phase 1b trial of its CB1 inverse agonist aimed at treating obesity. The study indicated the drug lowered rates of depression, anxiety, irritability a…